These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 32305434)

  • 1. Prediction of response to biological treatment with monoclonal antibodies in severe asthma.
    Kroes JA; Zielhuis SW; van Roon EN; Ten Brinke A
    Biochem Pharmacol; 2020 Sep; 179():113978. PubMed ID: 32305434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of refractory asthma with antibodies].
    Lommatzsch M
    Dtsch Med Wochenschr; 2016 Jun; 141(11):790-3. PubMed ID: 27254629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologic agents for severe asthma patients: clinical perspectives and implications.
    Caruso M; Morjaria J; Emma R; Amaradio MD; Polosa R
    Intern Emerg Med; 2018 Mar; 13(2):155-176. PubMed ID: 29238905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
    Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
    Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Efficacy of Anti IL-4, IL-5 and IL-13 Drugs for Treatment of Eosinophilic Asthma: A Network Meta-analysis.
    Iftikhar IH; Schimmel M; Bender W; Swenson C; Amrol D
    Lung; 2018 Oct; 196(5):517-530. PubMed ID: 30167841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical profile of benralizumab in the management of severe eosinophilic asthma.
    Menzella F; Lusuardi M; Galeone C; Facciolongo N; Zucchi L
    Ther Adv Respir Dis; 2016 Dec; 10(6):534-548. PubMed ID: 27612492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of biologics used in the treatment of asthma.
    Neunie OAM; Rabbani W; Baker D; Chambers ES; Pfeffer PE; Kang AS
    Hum Antibodies; 2024; 32(3):121-128. PubMed ID: 38905039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severe asthma: When to resort to biological agents.
    Tenero L; Rossignoli S; Piacentini G
    Pediatr Allergy Immunol; 2020 Feb; 31 Suppl 24():37-39. PubMed ID: 32017206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-IL-5 monoclonal antibodies for the treatment of asthma: an update.
    Walsh GM
    Expert Opin Biol Ther; 2020 Oct; 20(10):1237-1244. PubMed ID: 32529893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [PERSONALIZED TREATMENT OF ASTHMA: THE ISSUE OF ANTI-INTERLEUKIN-5 ANTIBODIES].
    Louis R; Demarche S; Van Hees T; Schleich F
    Rev Med Liege; 2015; 70(5-6):306-9. PubMed ID: 26285457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
    Hilvering B; Xue L; Pavord ID
    Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarkers in the clinical development of asthma therapies.
    Staton TL; Choy DF; Arron JR
    Biomark Med; 2016; 10(2):165-76. PubMed ID: 26764286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibodies for the treatment of refractory asthma.
    Hambly N; Nair P
    Curr Opin Pulm Med; 2014 Jan; 20(1):87-94. PubMed ID: 24275927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IgE and eosinophils as therapeutic targets in asthma.
    Patel TR; Sur S
    Curr Opin Allergy Clin Immunol; 2017 Feb; 17(1):42-49. PubMed ID: 27906698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mepolizumab and Benralizumab in Severe Eosinophilic Asthma: Preliminary Results of a Proteomic Study.
    Vantaggiato L; Perruzza M; Refini RM; Bergantini L; d'Alessandro M; Cameli P; Perruzza D; Bini L; Bargagli E; Landi C
    Lung; 2020 Oct; 198(5):761-765. PubMed ID: 32691140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Omalizumab and mepolizumab in the landscape of biological therapy for severe asthma in children: how to choose?
    Giovannini M; Mori F; Barni S; de Martino M; Novembre E
    Ital J Pediatr; 2019 Nov; 45(1):151. PubMed ID: 31779657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study.
    Albers FC; Müllerová H; Gunsoy NB; Shin JY; Nelsen LM; Bradford ES; Cockle SM; Suruki RY
    J Asthma; 2018 Feb; 55(2):152-160. PubMed ID: 28622052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Current State of Biologic Therapies for Treatment of Refractory Asthma.
    Mavissakalian M; Brady S
    Clin Rev Allergy Immunol; 2020 Oct; 59(2):195-207. PubMed ID: 31981048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Emerging Role for Exhaled Nitric Oxide in Guiding Biological Treatment in Severe Asthma.
    Rolla G; Heffler E; Pizzimenti S; Michils A; Malinovschi A
    Curr Med Chem; 2020; 27(42):7159-7167. PubMed ID: 32660394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mepolizumab: First Global Approval.
    Keating GM
    Drugs; 2015 Dec; 75(18):2163-9. PubMed ID: 26603873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.